This article is more than 5 years old. Information may no longer be current.
Top stories in endocrinology: Men with hypogonadism have new testosterone therapy choices, plan caps out-of-pocket insulin costs
Click Here to Manage Email Alerts
The top stories in endocrinology last week were the development of three new testosterone therapies that offer innovative drug delivery options for men with hypogonadism and that Cigna and Express Scripts announced a plan to cap out-of-pocket insulin costs at $25 for a 30-day supply for eligible plan members with diabetes.
Other highlights included findings that suggested adjustments that targeted specific bacteria in the gut microbiome may help patients with polycystic ovary syndrome, a study that detailed the recovery of healthy men who used nonprescribed androgens to improve athletic performance and a report that provided insight into a Congressional hearing about rising insulin prices. – by Melissa J. Webb
New testosterone therapies offer options for men with hypogonadism
Three new testosterone therapies offer innovative drug delivery options for men with hypogonadism that improve patient satisfaction while avoiding risks related to secondary exposure, according to several speakers at the Androgen Society annual meeting. Read more.
Cigna, Express Scripts to cap out-of-pocket insulin costs at $25 per month
Cigna and Express Scripts announced a plan to cap out-of-pocket insulin costs at $25 for a 30-day supply for eligible plan members with diabetes, according to a press release from the companies. Read more.
Gut microbiome could hold key for polycystic ovary syndrome treatment
Adjustments targeting specific bacteria in the gut microbiome may be an effective strategy for treating polycystic ovary syndrome, according to findings presented at the Endocrine Society Annual Meeting. Read more.
Spermatogenesis recovery slow after use of performance-enhancing drugs
Healthy men who used nonprescribed androgens to improve athletic performance experienced a slow recovery of suppressed testicular function after stopping drug use, with time to recovery ranging from 9 to 18 months, according to findings presented at the Endocrine Society annual meeting. Read more.
Physicians, advocates testify to insulin rationing due to unpredictable, high pricing
Diabetes stakeholders and patient advocates once again brought their concerns regarding rising insulin prices before Congress, seeking a solution for people with diabetes who struggle to afford a lifesaving medication and demanding accountability from an often-opaque drug supply system. Read more.